Denali Enters Into a $275M Funding Deal With Royalty Pharma

Key Takeaways Denali struck a $275M funding deal with Royalty Pharma tied to tividenofusp alfa.RPRX will pay up to $275M for royalty rights contingent on U.S. and EU approvals.Tividenofusp alfa's BLA review now targets April 5, 2026, after a major amendment submission.Denali Therapeutics Inc. (DNLI) has announced a funding agreement with Royalty Pharma plc (RPRX) for $275 million. The stock gained 5.84% following the announcement.The deal centers on future net sales of Denali’s lead drug candidate, tivideno ...